ADC Therapeutics Secures $60 Million in PIPE Financing, Enhancing Commercial Expansion of ZYNLONTA

Strategic Insights -

ADC Therapeutics, a global leader in antibody drug conjugates (ADCs), has announced a $60 million private investment in public equity (PIPE) financing, securing the equity securities from institutional investors led by TCGX and including participation from Redmile Group and other existing investors. This strategic move aims to further strengthen the company's balance sheet and invest in the commercial expansion of ZYNLONTA, a CD19-directed ADC, while also preparing for the potential relaunch in 2027.

ADC Therapeutics intends to utilize the net proceeds from the PIPE financing to invest in the commercial expansion of ZYNLONTA, strengthen its balance sheet, and fund working capital and general corporate purposes. The company expects to use the net proceeds of approximately $57.6 million after deducting placement agent fees and estimated offering expenses to have a total of $292.3 million in cash and cash equivalents as of September 30, 2025.

Key Takeaways:

  • ADC Therapeutics secured a $60 million private investment in public equity (PIPE) financing.
  • The PIPE is led by TCGX and includes participation from Redmile Group and other existing investors.
  • The company plans to use the net proceeds to invest in the commercial expansion of ZYNLONTA, strengthen its balance sheet, and fund working capital and general corporate purposes.
  • ZYNLONTA is a CD19-directed ADC that has received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.
  • The company expects net product revenues from sales of ZYNLONTA to be approximately $15.8 million for the third quarter ended September 30, 2025.

Statistics:

  • The PIPE announced by ADC Therapeutics amounts to $60 million, with a net total of $57.6 million after deducting placement agent fees and estimated offering expenses.
  • ADC Therapeutics expects to have a total of $292.3 million in cash and cash equivalents as of September 30, 2025, following the realization of the net proceeds from the PIPE.
  • ZYNLONTA's net product revenue for the third quarter ended September 30, 2025, is anticipated to be approximately $15.8 million.

Sources:

  • The original press release by ADC Therapeutics as stated on PRNewswire.
  • The Securities Act of 1933, specifically Section 4(a)(2), for the exemptions stated for the offer and sale of the securities.
  • The company's Annual Report on Form 10-K for risk factors and other financial information.
  • The U.S. Securities and Exchange Commission for the company's SEC filings and reporting.